As filed with the Securities and Exchange Commission on November 14, 2025 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Jade Biosciences, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Nevada 2836 83-137788 (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Identification No.) 221 Crescent St., Buil ...

Core Insights - Relmada Therapeutics has experienced a transformational year in 2025, with significant progress in its clinical development and strategic initiatives [1] Strategic Review and Portfolio Expansion - A comprehensive strategic review was completed, reaffirming the mission to develop life-changing treatments and diversify the portfolio [2] - Two new Phase 2 product candidates were added, enhancing the long-term value proposition of the company [2] NDV-01 Development - NDV-01 has shown a 91% complete response rate in a Phase 2 study for non-muscle invasive bladder cancer (NMIBC), affecting approximately 600,000 patients in the U.S. [2] - Preparations are underway to initiate a Phase 3 registrational trial in the first half of 2026, including regulatory filings and manufacturing scale-up [3][8] - The NDV-01 program is further supported by the addition of two experts in bladder cancer to the team [4] Sepranolone Advancement - Positive proof-of-concept data in Tourette's syndrome indicates potential for sepranolone in treating compulsive disorders [5] - A Phase 2 study for sepranolone in Prader-Willi Syndrome (PWS) is planned to begin in the first half of 2026, targeting a rare genetic disorder affecting 350,000–400,000 people worldwide [5][13] Key Upcoming Milestones - Upcoming milestones include Phase 2 results for NDV-01 in Q4 2025 and Q1 2026, product supply scale-up in the second half of 2025, and U.S. IND clearance in the first half of 2026 [8] - The initiation of the Phase 3 registrational trial for NDV-01 is also scheduled for the first half of 2026 [8] Company Outlook - The company remains optimistic about its future, with the progress of NDV-01 and sepranolone, alongside a strengthened team, positioning it well for value creation [9]

Core Viewpoint - Rongchang Biologics (09995) has shown a significant stock increase of over 4%, currently trading at 92.4 HKD, with a transaction volume of 625 million HKD. The company reported a strong performance in its mid-2025 results, driven by robust sales growth in its immunotherapy and oncology products [1][1]. Financial Performance - The company reported product sales and R&D service revenue of 1.092 billion RMB, representing a year-on-year increase of 47.6% [1]. - R&D expenses decreased by 19.7% to 647 million RMB, while the net loss was approximately 450 million RMB, a reduction of 42.4% year-on-year [1]. Product Development and Market Potential - The revenue increase is primarily attributed to the commercialization of its immunotherapy product, Tai Tasi, and the oncology product, Vidi Xi Tuo, which have seen strong sales growth [1]. - Huatai Securities expresses optimism about the company's long-term growth potential, forecasting a revenue increase of over 30% for the year [1]. - The company is expected to enter commercialization with RC28 upon achieving authorization, and the global competitiveness of Tai Tasi in indications like MG is viewed positively [1]. - The Phase III trial for Vidi Xi Tuo is accelerating, and RC148 has shown positive efficacy signals in IO-resistant patients, indicating strong demand from multinational corporations for PD-1/VEGF dual antibodies [1].

As filed with the U.S. Securities and Exchange Commission on September 23, 2024. Registration No. 333-279771 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 4 TO FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 MEDICUS PHARMA LTD. (Exact name of Registrant as specified in its charter) ______________________________ Ontario, Canada 2834 98-1778211 (State or other jurisdiction of (Primary Standard Industrial (I.R.S. Employer incorporation or organization) ...